Civitas secures $38 million in series B

Civitas Therapeutics Inc. (Chelsea, Mass.) secured $38 million in a series B round led by new investor Bay City Capital. New investors RA Capital and another undisclosed fund participated along with existing investors, including Alkermes plc (NASDAQ:ALKS); Canaan Partners; Fountain Healthcare Partners; and Longitude Capital. Bay City Capital's Rob Hopfner and RA Capital's Rajeev Shah will join Civitas' board. ...